BridgeBio Pharma, Inc. — Director's Dealing 2023

Feb 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-02-10

Reporting Person: Kumar Neil (Director, CEO and President)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-10	Stock Option (Right to Buy)	$11.41	A	624652	Acquired	2033-02-09	Common Stock (624652)	Direct
2023-02-10	Restricted Stock Units	$	A	536704	Acquired		Common Stock (536704)	Direct

Footnotes

F1: The shares subject to this option vest and become exercisable in 48 equal monthly installments after February 10, 2023, such that all of the shares subject to the option shall be vested and exercisable on February 10, 2027, subject to the Reporting Person's continued service to the Issuer through each such date.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, such that all of the underlying shares shall be vested on February 16, 2027, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSU's have no expiration date.